Industry Profile

3D Bioprinting and Bioinks

Target researchers — Tissue engineers, regenerative medicine researchers, drug testing scientists, organ-on-chip developers, and biomaterials scientists fabricating living 3D constructs.

3D bioprinting deposits living cells, bioinks, and hydrogels layer by layer to fabricate three-dimensional tissue constructs that recapitulate the architecture and function of native organs far more accurately than flat 2D culture. CELLINK (now BICO), Organovo, Aspect Biosystems, RegenHU, and Advanced Solutions Life Sciences supply extrusion-, inkjet-, laser-assisted, and stereolithography-based bioprinters alongside tailored bioink portfolios—alginate, GelMA, fibrin, decellularized ECM—optimized for printability and cell viability. Researchers procure complete bioprinting workstations, crosslinking modules, integrated incubation chambers, and post-print culture consumables. The pharmaceutical industry increasingly adopts bioprinted liver, cardiac, and kidney models to reduce animal use in ADMET screening, while EU Horizon and NIH funding channels drive academic procurement of multi-material bioprinting systems. Sell to Scientists CLI matches research labs with bioink formulation suppliers, printer validation service providers, and academic bioprinting core facilities worldwide.

Key Companies